JP2017155057A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017155057A5 JP2017155057A5 JP2017116440A JP2017116440A JP2017155057A5 JP 2017155057 A5 JP2017155057 A5 JP 2017155057A5 JP 2017116440 A JP2017116440 A JP 2017116440A JP 2017116440 A JP2017116440 A JP 2017116440A JP 2017155057 A5 JP2017155057 A5 JP 2017155057A5
- Authority
- JP
- Japan
- Prior art keywords
- parvovirus
- pharmaceutical composition
- composition according
- cancer
- bcl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000125945 Protoparvovirus Species 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 102100013894 BCL2 Human genes 0.000 claims 4
- 108060000885 BCL2 Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 241000700159 Rattus Species 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 241000702321 Microvirus Species 0.000 claims 1
- 241000702623 Minute virus of mice Species 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 201000010915 glioblastoma multiforme Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 230000000306 recurrent Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
Claims (8)
- （ａ）パルボウイルスおよび（ｂ）Ｂｃｌ−２阻害剤を含有する腫瘍を治療するための医薬組成物であって、前記パルボウイルスは、Ｈ−１（Ｈ−１ＰＶ）、または、ＬｕＩＩＩ、マウス微小ウイルス（ＭＭＶ）、マウスパルボウイルス（ＭＰＶ）、ラット微小ウイルス（ＲＭＶ）、ラットパルボウイルス（ＲＰＶ）およびラットウイルス（ＲＶ）から選択される関連齧歯類パルボウイルスである医薬組成物。
- （ａ）前記パルボウイルスおよび（ｂ）前記Ｂｃｌ−２阻害剤を別個の実体として含有する請求項１に記載の医薬組成物。
- 前記パルボウイルスおよび前記Ｂｃｌ−２阻害剤が連続的に投与されることを特徴とする、請求項１または２に記載の医薬組成物。
- 充実性腫瘍および／または癌始原幹細胞を治療するための、請求項１または２に記載の医薬組成物。
- パルボウイルス細胞毒性に対して抵抗性である腫瘍を治療するための、請求項１または２に記載の医薬組成物。
- 前記腫瘍は、脳腫瘍、膵臓癌、子宮頸癌、肺癌、頭頸部癌、乳癌または大腸癌である、請求項１または２に記載の医薬組成物。
- 神経膠腫または再発性多形性膠芽細胞腫を治療するための、請求項１または２に記載の医薬組成物。
- 前記パルボウイルスおよび／またはＢｃｌ−２阻害剤が腫瘍内または静脈内投与されることを特徴とする、請求項１または２に記載の医薬組成物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13003664.3 | 2013-07-22 | ||
| EP20130003664 EP2829284A1 (en) | 2013-07-22 | 2013-07-22 | Cancer therapy with a parvovirus combined with a Bcl-2 inhibitor |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016528375A Division JP6195988B2 (ja) | 2013-07-22 | 2014-07-22 | パルボウイルスにＢｃｌ−２阻害剤を併用する癌療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017155057A JP2017155057A (ja) | 2017-09-07 |
| JP2017155057A5 true JP2017155057A5 (ja) | 2017-11-16 |
Family
ID=48856486
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016528375A Active JP6195988B2 (ja) | 2013-07-22 | 2014-07-22 | パルボウイルスにＢｃｌ−２阻害剤を併用する癌療法 |
| JP2017116440A Pending JP2017155057A (ja) | 2013-07-22 | 2017-06-14 | パルボウイルスおよびＢｃｌ−２阻害剤を含有する医薬組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016528375A Active JP6195988B2 (ja) | 2013-07-22 | 2014-07-22 | パルボウイルスにＢｃｌ−２阻害剤を併用する癌療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9889169B2 (ja) |
| EP (2) | EP2829284A1 (ja) |
| JP (2) | JP6195988B2 (ja) |
| AU (1) | AU2014295442B2 (ja) |
| CA (1) | CA2914420C (ja) |
| DK (1) | DK3024491T3 (ja) |
| ES (1) | ES2636768T3 (ja) |
| WO (1) | WO2015010782A1 (ja) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3069724A1 (en) * | 2015-03-19 | 2016-09-21 | Deutsches Krebsforschungszentrum | Lung cancer therapy with a rodent parvovirus |
| CN109195593A (zh) * | 2016-03-15 | 2019-01-11 | 奥莱松基因组股份有限公司 | 用于治疗实体瘤的lsd1抑制剂的组合 |
| AU2016397532A1 (en) * | 2016-03-17 | 2018-08-23 | Deutsches Krebsforschungszentrum | Lung cancer therapy with a parvovirus |
| EP3225253A1 (en) | 2016-04-01 | 2017-10-04 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor |
| CN106177955B (zh) * | 2016-08-18 | 2018-03-16 | 广州威溶特医药科技有限公司 | Bcl‑xL抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用 |
| EP3624811A4 (en) * | 2017-05-19 | 2021-03-10 | The Regents of The University of California | ANTIBODY-BASED CHEMICAL INDUCED DIMERIZER (ABCID) AS A MOLECULAR SWITCH FOR REGULATING CELL THERAPIES |
| EP3657172A1 (en) | 2018-11-22 | 2020-05-27 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Method for predicting the clinical response of oncolytic parvovirus h1 (h-1pv) treatment in a patient suspected of suffering from cancer by measuring the expression levels of laminins and/or galectins as biomarkers in a patient´s sample |
| US20240041833A1 (en) | 2020-12-21 | 2024-02-08 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Pharmaceutical combination product comprising a protoparvovirus and an antiviral benzimidazole and uses thereof for treating cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2402138T3 (es) * | 2007-12-28 | 2013-04-29 | Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts | Terapia contra el cáncer con un parvovirus combinado con quimioterapia |
| EP2366398A1 (en) | 2010-03-17 | 2011-09-21 | Deutsches Krebsforschungszentrum | Cancer therapy with a parvovirus combined with an HDAC inhibitor |
-
2013
- 2013-07-22 EP EP20130003664 patent/EP2829284A1/en not_active Withdrawn
-
2014
- 2014-07-22 JP JP2016528375A patent/JP6195988B2/ja active Active
- 2014-07-22 ES ES14752272.6T patent/ES2636768T3/es active Active
- 2014-07-22 CA CA2914420A patent/CA2914420C/en active Active
- 2014-07-22 WO PCT/EP2014/002001 patent/WO2015010782A1/en active Application Filing
- 2014-07-22 DK DK14752272.6T patent/DK3024491T3/en active
- 2014-07-22 AU AU2014295442A patent/AU2014295442B2/en active Active
- 2014-07-22 EP EP14752272.6A patent/EP3024491B1/en active Active
-
2015
- 2015-12-07 US US14/960,608 patent/US9889169B2/en active Active
-
2017
- 2017-06-14 JP JP2017116440A patent/JP2017155057A/ja active Pending
- 2017-12-28 US US15/856,241 patent/US10406185B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017155057A5 (ja) | ||
| JP2016041733A5 (ja) | ||
| EA201790476A1 (ru) | Аминопиридилоксипиразольные соединения | |
| MY197018A (en) | Substituted tricyclics and method of use | |
| JP2016183160A5 (ja) | ||
| JP2017509667A5 (ja) | ||
| MY184586A (en) | Adenoassociated virus vectors for the treatment of mucopolysaccharidoses | |
| WO2016054598A3 (en) | Antibodies that bind ebola glycoprotein and uses thereof | |
| MX2017015879A (es) | Composiciones de hidroxipropil beta-ciclodextrina y metodos. | |
| WO2015127140A3 (en) | Marburg monoclonal antibodies | |
| WO2017117070A8 (en) | Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof | |
| JP2016540015A5 (ja) | ||
| JP2016520594A5 (ja) | ||
| JP2017537928A5 (ja) | ||
| JP2009505991A5 (ja) | ||
| EP4331622A3 (en) | Integrin binding peptides and uses thereof | |
| JP2016540019A5 (ja) | ||
| JP2020531778A5 (ja) | ||
| JP2013541586A5 (ja) | ||
| MX2017013928A (es) | Composiciones para limpieza de colon y tratamiento de trastornos gastrointestinales. | |
| CA3073766A1 (en) | Process for the preparation of tubulysins and intermediates thereof | |
| WO2015001541A3 (en) | Pharmaceutical film composition | |
| JP2019515942A5 (ja) | ||
| JP2016533190A5 (ja) | ||
| JP2018529625A5 (ja) |